Psychosocial Complexity Does Not Predict Withdrawal During Methadone-Buprenorphine Transfer

This cohort challenges the practice of screening out complex patients from methadone-to-buprenorphine transfer, showing withdrawal follows a predictable trajectory independent of psychosocial risk factors.

buprenorphinemethadoneopioid agonist therapyopioid use disordermethadone-buprenorphine transferprecipitated withdrawalCOWSSOWSprospective cohortlow-dose inductionstop-and-start Pain / Palliative Care

Background Information

Withdrawal during methadone-to-buprenorphine transfers peaks and is predictable.

Understanding withdrawal experiences during methadone-to-buprenorphine transfers (MBT) can improve the management and support for patients in opioid agonist therapy. Withdrawal peaked around Day 5 and was not influenced by psychosocial factors. Low-dose transfer delayed peak withdrawal by 2.3 days and increased the severity slightly compared to stop-and-start methods. These results suggest that clinicians should plan for expected withdrawal without selecting patients based on perceived psychosocial complexity during MBT. Withdrawal during MBT is predictable, allowing strategic planning for patient support.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Tremonti C, Mills L, Lintzeris N, Blogg J, Jamshidi N, Harjanto R, Blazey A, Montebello M, Ismay C, Page R, Buckley NA, Perananthan V, Haber PS

Citation: Tremonti C, Mills L, Lintzeris N, et al. Patient Experience of Withdrawal During Methadone-Buprenorphine Transfer: A Prospective Cohort Study. Drug and alcohol review. 2026;45(5):e70211. doi:10.1111/dar.70211

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →